High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C
- 23 June 2010
- journal article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 25 (7), 1276-1280
- https://doi.org/10.1111/j.1440-1746.2010.06295.x
Abstract
BACKGROUND AND AIM: Prisoners have a high prevalence of injection drug use (IDU) and chronic hepatitis C (CHC) infection. Treatment of CHC in these patients is effective; however, their long-term outcomes following treatment are unknown. We determined the durability of a sustained virological response (SVR) in prisoners treated for CHC. METHODS: Patients were treated as part of routine clinical practice with interferon (IFN) and ribavirin. A retrospective review of medical records and a computerized pathology system was performed for clinical and laboratory information. RESULTS: Seventy-four prisoners (70 males, mean age 34 years, IDU in 55%) were evaluable for a SVR over a 12-year period to December 2008; the mean follow-up period was 1243 days. Genotype 1, 2, 3, and 6 infection was present in 18, three, 38 and three patients, respectively; the genotype was unknown in 12. Three out of 52 biopsied had cirrhosis. Standard IFN was administered to 25 (34%; 11 with ribavirin), and 49 received pegylated IFN and ribavirin; one did not complete treatment, and two had breakthrough relapses. The end-of-treatment response was achieved in 57 and SVR in 53; 14 were non-responders. Five male patients, four with unknown genotypes and treated with standard IFN alone, relapsed late (following SVR, 9%). Five patients, all treated with pegylated IFN and ribavirin, were reinfected (one prior to and four following SVR). CONCLUSIONS: Prisoners are often successfully treated for CHC. However, this retrospective study indicates that there is a high (17%) prevalence of late recurrence of viremia that is likely a reflection of reinfection due to ongoing risk-taking behavior.John P. Bate, Anton J. Colman, Peter J. Frost, David R. Shaw and Hugh A.J. HarleKeywords
This publication has 27 references indexed in Scilit:
- Treatment Outcomes With Pegylated Interferon and Ribavirin for Male Prisoners With Chronic Hepatitis CJournal of Clinical Gastroenterology, 2009
- Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: A randomized controlled trialHepatology, 2009
- Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibodyLiver International, 2009
- Diagnosis, management, and treatment of hepatitis C: An updateHepatology, 2008
- Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patientsHepatology, 2008
- Clinical Outcomes of Hepatitis C Treatment in a Prison Setting: Feasibility and Effectiveness for Challenging Treatment PopulationsClinical Infectious Diseases, 2008
- Treating hepatitis C in the prison population is cost-savingHepatology, 2008
- Prisons and HCV: a review and a report on an experience in New South Wales AustraliaInternational Journal of Prisoner Health, 2008
- Feasibility and Outcome of HCV Treatment in a Canadian Federal Prison PopulationAmerican Journal of Public Health, 2005
- Treatment of Chronic Hepatitis C Virus in the Virginia Department of Corrections: Can Compliance Overcome Racial Differences to Response?The American Journal of Gastroenterology, 2004